SCHEMBL29548528

SCHEMBL29548528

CN(C)c1ccc2ccccc2c1N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
CYP2A6 P11509 3/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CHEK1 O14757 1/20 0.45
NEK2 P51955 1/20 0.45
LIMK1 P53667 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
MCL1 Q07820 1/20 0.44
EP300 Q09472 1/20 0.44
KAT2B Q92831 1/20 0.44
KAT8 Q9H7Z6 1/20 0.44
SIGMAR1 Q99720 1/20 0.42
HPRT1 P00492 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380067 1.00 ALDH1A1 (0.46) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL28337731 0.82 MCL1 (0.41) ALDH1A1CYP2A6HSD17B10TDP1CHEK1
SCHEMBL13021638 0.78 TSHR (0.56) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL1834494 0.78 CYP1A2 (0.56) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL29861991 0.78 TSHR (0.56) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL235342 0.77 EP300 (0.57) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL9296111 0.77 CYP2A6 (0.44) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL5172330 0.77 CHEK1 (0.48) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL235341 0.77 MAPT (0.55) ALDH1A1CYP2A6TSHRHSD17B10TDP1
SCHEMBL25649454 0.77 HSD17B10 (0.44) ALDH1A1CYP2A6TSHRHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008676-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE IDEMITSU KOSAN CO.,LTD. (JP) 2026-01-08 US disclosed
US-20250201909-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE IDEMITSU KOSAN CO.,LTD. (JP) 2025-06-19 US disclosed
EP-4557317-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE Idemitsu Kosan Co.,Ltd. (JP) 2025-05-21 EP disclosed
EP-4503065-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE Idemitsu Kosan Co.,Ltd. (JP) 2025-02-05 EP disclosed
US-12119442-B2 Method for producing sulfide solid electrolyte IDEMITSU KOSAN CO., LTD. (JP) 2024-10-15 US disclosed
WO-2024029419-A1 POSITIVE ELECTRODE MIXTURE, LITHIUM ION BATTERY, POSITIVE ELECTRODE MIXTURE COMPOSITION, AND POSITIVE ELECTRODE MIXTURE PRODUCTION METHOD 出光興産株式会社 2024-02-08 WO disclosed
WO-2022102696-A2 SOLID ELECTROLYTE PRODUCTION METHOD 出光興産株式会社 2022-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008676-A1 METHOD FOR MANUFACTURING SULFIDE SOLID ELECTROLYTE CACNA1S, CACNA1A, VRK2 ALDH1A1 1394/4885CYP2A6 3960/4885TSHR 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.